MedPath

Jupiter Neurosciences Teams with Catalent to Manufacture JOTROL for Parkinson's Disease Trial

• Jupiter Neurosciences has partnered with Catalent Pharma Solutions to produce JOTROL softgel capsules, a resveratrol-based therapeutic, for an upcoming Phase 2a clinical trial in Parkinson's disease.

• The manufacturing agreement includes production of both active and placebo batches using an optimized softgel formulation, leveraging Catalent's expertise in pharmaceutical manufacturing.

• The Phase 2a trial will assess JOTROL's safety, tolerability, and pharmacokinetics/pharmacodynamics in Parkinson's patients over a three-month study period.

Jupiter Neurosciences Inc. has established a strategic manufacturing partnership with Catalent Pharma Solutions LLC to produce JOTROL softgel capsules for its upcoming Phase 2a clinical trial targeting Parkinson's disease. The collaboration marks a significant step forward in advancing Jupiter's novel resveratrol-based therapeutic platform.

Manufacturing Partnership Details

The agreement tasks Catalent with manufacturing clinical batches of JOTROL using an optimized softgel formulation. The production scope encompasses both active drug and placebo capsules essential for the planned Parkinson's disease study. This partnership leverages Catalent's established expertise in pharmaceutical manufacturing and their capability to meet precise production timelines.
Christer Rosén, Chairman and CEO of Jupiter Neurosciences, emphasized the strategic importance of the collaboration, stating, "Securing an experienced CDMO leader like Catalent is a critical step as we advance JOTROL into clinical development for Parkinson's disease." He further highlighted that "Catalent's industry-leading expertise in pharmaceutical manufacturing and its ability to scale production efficiently according to a tight timeline will help us maintain momentum in our development program and support our goal of delivering innovative therapies to patients."

Upcoming Clinical Trial

The Phase 2a clinical trial represents a crucial evaluation phase for JOTROL, focusing on three primary aspects:
  • Safety assessment
  • Tolerability profile
  • Pharmacokinetics and pharmacodynamics (PK/PD) characteristics
The study is designed to span three months, during which Parkinson's disease patients will receive the investigational treatment. This trial will provide essential data to guide the further development of JOTROL as a potential therapeutic option for Parkinson's disease patients.

JOTROL Platform Technology

JOTROL, Jupiter's proprietary therapeutic, is built on a patented resveratrol-based platform. Resveratrol, known for its potential neuroprotective properties, has been optimized in JOTROL's formulation to potentially address the underlying mechanisms of Parkinson's disease. The softgel capsule format has been specifically chosen to optimize drug delivery and patient compliance.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Serina Therapeutics Secures $10M for Novel Parkinson's Drug Delivery System Trial

Huntsville-based Serina Therapeutics has secured $10 million funding from UK's JuvVentures to advance their innovative drug delivery system for Parkinson's disease treatment.
The biotechnology company is developing an enhanced delivery method for apomorphine, combining their proprietary technology with Enable Injections' wearable device for improved patient administration.

Jupiter Neurosciences Advances JOTROL Platform with Phase 2a Parkinson's Trial and Consumer Product Launch

Jupiter Neurosciences has secured strategic partnerships with Zina Biopharmaceuticals and Catalent Pharma Solutions to advance JOTROL, their enhanced resveratrol formulation, into Phase 2a trials for Parkinson's disease.
The company's JOTROL platform demonstrates nine times higher bioavailability compared to traditional resveratrol formulations, addressing a key limitation in previous clinical applications of the compound.

Xilio Therapeutics Reports Promising Phase II Results for Vilastobart Combination in Colorectal Cancer

Xilio Therapeutics has announced positive Phase II clinical trial results for their vilastobart combination therapy in colorectal cancer patients. The study demonstrates meaningful clinical benefits, potentially offering a new treatment option for patients with advanced colorectal cancer.

Johnson & Johnson to Acquire Intra-Cellular Therapies for $14.6 Billion, Bolstering Neuroscience Portfolio

Johnson & Johnson (J&J) will acquire Intra-Cellular Therapies for $14.6 billion, gaining access to Caplyta and a pipeline of CNS disorder treatments.
Caplyta, approved for schizophrenia and bipolar depression, has a supplemental NDA under FDA review for major depressive disorder (MDD) as adjunctive therapy.

Jupiter Neurosciences Raises $11 Million in IPO to Advance Parkinson's Drug

Jupiter Neurosciences successfully completed its initial public offering, raising $11 million through the sale of 2,750,000 shares at $4.00 per share.
The company intends to use the IPO proceeds to fund a Phase II clinical trial of JOTROL™ for Parkinson's Disease and expand business activities in South-East Asia.

Jaguar Health's Napo Therapeutics Advances Crofelemer for Rare Intestinal Diseases in Europe

Napo Therapeutics, a Jaguar Health company, has been recognized as 'Best Pharmaceuticals Innovator of the Year - Europe'.
Crofelemer, a plant-based drug, is being advanced for microvillus inclusion disease (MVID) and short bowel syndrome (SBS).

Nipocalimab Shows Promise in Phase II Trial for Sjögren's Disease

Johnson & Johnson's nipocalimab met the primary endpoint in a Phase II trial for moderate-to-severe Sjögren's disease, demonstrating a significant change in ClinESSDAI score.
Patients with high anti-Ro and anti-La autoantibodies showed the greatest improvements, with a 77% reduction in IgG and total IgG autoantibodies.

Nipocalimab Granted FDA Breakthrough Therapy Designation for Sjögren's Disease

The FDA granted Breakthrough Therapy Designation to nipocalimab for moderate-to-severe Sjögren's Disease, an autoantibody disease lacking approved advanced treatments.
This marks the second BTD for nipocalimab, previously recognized for its potential in treating alloimmunized pregnant individuals at high risk of HDFN.

J&J Discontinues Seltorexant Trial in Alzheimer's, Citing Portfolio Prioritization

Johnson & Johnson has discontinued its Phase II clinical trial of seltorexant for Alzheimer's disease due to portfolio prioritization.
Seltorexant, a human orexin-2 receptor selective agonist, showed promise in Phase III trials for major depressive disorder with insomnia.

J&J Expands Cell Therapy Portfolio with New CAR-T Deals

Johnson & Johnson has secured rights to two experimental cell therapies for blood cancer, aiming to build on its success in CAR-T treatment development. The deal with Cellular Biomedicine Group involves a $245 million upfront payment for access to therapies showing promise in early-phase trials for recurrent diffuse large B cell lymphoma.

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy